Ketorolac Tromethamine Injection by Sagent Pharmaceuticals Recalled: AttorneyOne Monitors and Keeps Consumers Informed

Share Article

On October 6, the FDA announced that three lots of Ketorolac Tromethamine Injection, USP, 30mg/mL single-dose vials, distributed by Sagent, are recalled due to incorrect labeling. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

Ketorolac Tromethamine Injection by Sagent Pharmaceuticals Recalled

Ketorolac Tromethamine Injection by Sagent Pharmaceuticals Recalled

We are determined to keep an eye on FDA announcements concerning Ketorolac Tromethamine Injection and inform the public.

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Ketorolac Tromethamine Injection.

The US FDA announced on October 6, that three lots of Ketorolac Tromethamine Injection, USP, 30mg/mL single-dose vials, manufactured by Cadila Healthcare Limited and distributed by Sagent, are recalled due to incorrect labeling. Ketorolac Tromethamine Injection, USP, 30mg/mL is a nonsteroidal anti-inflammatory drug (NSAID) used for short-term management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.

FDA’s reason for the recall is that the affected product was labeled with the incorrect expiration date, that is longer than the known stability of the product.
The affected product lot numbers are: MP5021, MP5024 and MP5025, NDC numbers 25021-701-01 and 25021-701-02 with distribution dates from September 17, 2014 through October 1, 2014.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Ketorolac Tromethamine Injection and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA advises “Customers have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of and return the recalled lots of product.” And the Agency adds “Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.”

AttorneyOne.com has further information on Ketorolac Tromethamine Injection at the website including the latest major drug, food, and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/09/prweb12231514.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Attorney One
+1 877-230-7343
Email >
@Attorney_One
Follow >
Visit website